Literature DB >> 15537524

Prevention of dementia: lessons from SYST-EUR and PROGRESS.

Olivier Hanon1, Françoise Forette.   

Abstract

Hypertension is one of the principal risk factors for cerebrovascular diseases, closely correlated also with cognitive decline and dementia. Data from recent therapeutic trials (SYST-EUR, PROGRESS) open the way toward the prevention of dementia (vascular or Alzheimer's type) by antihypertensive treatments. The results of these two studies suggest different mechanisms of action of antihypertensive drugs in the prevention of cognitive decline. The use of angiotensin converting enzyme (ACE) inhibitors, with or without diuretics, resulted in decrease incidence of stroke-related dementia, but dementia without stroke was not reduced. With the dihydropyridine calcium antagonists, a reduction in both Alzheimer's type and vascular dementia was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537524     DOI: 10.1016/j.jns.2004.09.015

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

1.  The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration.

Authors:  J Ellul; N Archer; C M L Foy; M Poppe; H Boothby; H Nicholas; R G Brown; S Lovestone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

2.  Cognition and Hemodynamics.

Authors:  Vera Novak
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-10

Review 3.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Authors:  Daniel Paris; Corbin Bachmeier; Nikunj Patel; Amita Quadros; Claude-Henry Volmar; Vincent Laporte; Jim Ganey; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Fiona Crawford; Michael J Mullan
Journal:  Mol Med       Date:  2010-12-17       Impact factor: 6.354

Review 5.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.

Authors:  Elisabeth C W van Straaten; Danielle Harvey; Philip Scheltens; Frederik Barkhof; Ronald C Petersen; Leon J Thal; Clifford R Jack; Charles DeCarli
Journal:  J Neurol       Date:  2008-09-25       Impact factor: 4.849

7.  An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.

Authors:  Todd L Edwards; Margaret Pericak-Vance; Johnny R Gilbert; Jonathan L Haines; Eden R Martin; Marylyn D Ritchie
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

Review 8.  Vascular dementia: a review of recent evidence for prevention and treatment.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

9.  Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure.

Authors:  Michael J Firbank; Rebecca M Wiseman; Emma J Burton; Brian K Saxby; John T O'Brien; Gary A Ford
Journal:  J Neurol       Date:  2007-04-20       Impact factor: 4.849

10.  Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke.

Authors:  Johann Selvarajah; Marietta Scott; Stavros Stivaros; Sharon Hulme; Rachel Georgiou; Nancy Rothwell; Pippa Tyrrell; Alan Jackson
Journal:  Eur Radiol       Date:  2008-11-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.